Sera Prognostics, Inc.
SERA Healthcare Medical Devices
Sera Prognostics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $81,000.00, up 5.19% from fiscal 2024. In the quarter to June 2026, revenue grew 76.5%, EPS fell 12.5% and free cash flow fell 10.6%, each against the same quarter a year earlier.
Follow SERA
Sera Prognostics, Inc. (SERA) EV/Sales
As of 16 October 2026, Sera Prognostics, Inc. (SERA) trades at a EV/Sales of 822×. Over the past ten years it has ranged from −1,706× (September 2021) to 2,726× (October 2021); the current reading is higher than 65% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1,252× | (33.95%) |
| FY2024 | 1,895× | 322.18% |
| FY2023 | 449× | — |
| FY2022 | −155× | — |
| FY2021 | −24.3× | — |
| FY2020 | −1,525× | — |
| FY2019 | −1,525× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 649× | (32.29%) |
| Mar 2026 | 958× | (23.45%) |
| Dec 2025 | 1,252× | 9.87% |
| Sep 2025 | 1,139× | 28.51% |
| 20 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OM Outset Medical, Inc. compare | 0.2× |
| LUNG Pulmonx Corporation compare | 0.7× |
| ZOMDF Zomedica Corp. compare | 0.9× |
| LNSR LENSAR, Inc. compare | 1.1× |
| ECOR electroCore, Inc. compare | 1.9× |
| APYX Apyx Medical Corporation compare | 2.2× |
| HYPR Hyperfine, Inc. compare | 2.6× |
| LUCD Lucid Diagnostics Inc. compare | 14.3× |
| SERA Sera Prognostics, Inc. | 822× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)